Add BrightSurf on Google Email

New drug combination improves survival in patients with muscle-invasive bladder cancer

A new treatment approach combining immunotherapy with targeted cancer drug enfortumab vedotin improves survival in patients with muscle-invasive bladder cancer. The treatment reduces the risk of death by 42% and cancer recurrence or progression by 49% in patients unable to receive standard chemotherapy.

SourceUniversity of California - Los Angeles Health Sciences·JournalNew England Journal of Medicine·DateNov 9, 2026

Allison Institute convenes leading scientists and clinicians for fourth annual scientific symposium on frontiers of immunotherapy

The University of Texas M. D. Anderson Cancer Center hosted its fourth annual scientific symposium on frontiers of immunotherapy, featuring a panel discussion with five Nobel laureates and over 15 leading scientists and clinicians. The symposium focused on immune set points, exploring the regulatory mechanisms that determine immune sys...

Immune system protein is a cancer killer on its own, new study shows

A new study published in Cell reveals that perforin, a protein made by T cells and NK cells, can induce ferroptosis in tumor cells, a previously unknown mechanism of cell death. This discovery could have significant implications for understanding how cancers are killed by immune cells and could lead to new avenues for immunotherapy.

SourceMichigan Medicine - University of Michigan·JournalCell·TypeExperimental study·DateOct 29, 2026

NICHE-2: No disease recurrences after five years of follow-up

The NICHE-2 study demonstrates durable disease control with no disease recurrences in 111 patients with locally advanced mismatch repair-deficient colon cancer treated with short-course neoadjuvant immunotherapy. Circulating tumor DNA analysis reveals rapid molecular response to immunotherapy, with implications for treatment de-escalat...

SourceNetherlands Cancer Institute·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateOct 22, 2026

Swim Across America-funded cancer research leads to landmark FDA approval of immunotherapy for rectal cancer

A groundbreaking immunotherapy treatment for rectal cancer has received FDA approval, offering patients with locally advanced rectal cancer the possibility of eliminating their cancer without chemotherapy, radiation, or surgery. The treatment, developed through pioneering research at Memorial Sloan Kettering Cancer Center, has shown a ...

SourceSwim Across America·TypeRandomized controlled/clinical trial·DateOct 22, 2026

Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer in Phase 1b trial

The Phase 1b FURTHER trial revealed that firmonertinib achieved durable antitumor activity in patients with EGFR PACC-mutated non-small cell lung cancer, with 43% and 68% objective response rates at 160mg and 240mg daily doses, respectively. Patients with complete clearance of EGFR PACC mutations from their blood experienced higher res...

UCLA researchers identify key pathway that drives T-cell exhaustion in cancer immunotherapy

Researchers at UCLA Health Jonsson Comprehensive Cancer Center used CRISPR screen to identify key molecular pathway driving T-cell exhaustion in cancer-fighting immune cells. Disabling the pathway, CRL5, allowed engineered immune cells to stay active longer and fight solid tumors more effectively in preclinical studies.

SourceUniversity of California - Los Angeles Health Sciences·JournalCancer Immunology Research·DateOct 15, 2026

International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases

The updated consensus recommendations provide a shared framework to support patient safety and consistency in clinical practice while continuing to build the evidence base. Key findings include careful patient selection, multidisciplinary care, and long-term follow-up as essential for CAR T-cell therapy in autoimmune diseases.

SourceEuropean Society for Blood and Marrow Transplantation·JournalThe Lancet Rheumatology·DateOct 5, 2026

KRAS inhibition combined with CTLA-4 blockade overcomes immunotherapy resistance in KRAS-mutant gastric cancer

KRAS mutations define a distinct molecular subset of gastric adenocarcinoma with poor response to immunotherapy. KRAS inhibition combined with CTLA-4 blockade overcomes immunotherapy resistance by attenuating TGF-beta activity and impairing regulatory T cell function, sensitizing tumors to CTLA-4 immunotherapy.

SourceScience China Press·JournalScience China Life Sciences·DateOct 4, 2026

Immune cells defy textbook classifications

Researchers have discovered that γδ T cells use adaptive immune receptors to drive rapid, innate-like responses to tissue stress, inflammation, and cancer. These cells rely on the receptor to maintain and mount rapid tissue surveillance responses, making them a promising candidate for next-generation cancer immunotherapies.

SourceThe Francis Crick Institute·JournalNature·DateSep 30, 2026

Weill Cornell Medicine fall grants roundup

Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...

Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma

A Phase 1 clinical trial found that an investigational CAR-T therapy, anito-cel, led to high response rates and durable benefits in patients with relapsed/refractory multiple myeloma. Serious side effects were uncommon, and no delayed neurological complications were reported.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateSep 24, 2026

Researchers uncover dual role of B7-H3 in tumor immune suppression

Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.

Study unveils ‘plug-and-play’ CAR T technology designed to adapt as cancer changes

Researchers from City of Hope have developed a 'plug-and-play' CAR T technology that allows scientists to update engineered cancer-fighting immune cells after treatment. This technology, called meditope, enables the cells to adapt as tumors evolve, helping them to better control the cells and redirect them to attack different types of ...

SourceCity of Hope·JournalCancer Immunology Research·TypeExperimental study·DateSep 21, 2026

New molecules against hard-to-treat tumors

Researchers developed small molecules that activate macrophages to attack cancer cells, weakening the tumor's defenses against the immune system. The molecules, called Phagocytic Synapse Enhancers, were tested in cell cultures and animal models and showed promising results, slowing tumor growth and extending survival.

SourceUniversity of Basel·JournalCancer Research·DateSep 7, 2026

Adjuvant immunotherapy shows no survival benefit for NSCLC patients achieving pCR after neoadjuvant treatment

A real-world observational study found no significant survival benefit from post-surgery immunotherapy in NSCLC patients with pathological complete response after neoadjuvant chemoimmunotherapy. The study suggests that these patients may already derive the maximum benefit from neoadjuvant therapy alone.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeObservational study·DateSep 2, 2026

mRNA immunotherapy developed by UMass Chan scientists eliminates pancreatic tumors in mice

Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.

SourceUMass Chan Medical School·JournalNature Communications·TypeExperimental study·DateAug 25, 2026

Next-gen mRNA therapeutics get a new delivery vehicle

Researchers at Nagoya University developed a new delivery vehicle for circular RNA (cirRNA) using a novel lipid nanoparticle, FL0445-LNP, which improves the stability and efficacy of mRNA-based therapeutics. The technology has potential applications in cancer vaccines, genome editing, and protein supplements.

SourceNagoya University·JournalCell Biomaterials·TypeExperimental study·DateAug 19, 2026

Pusan National University researchers uncover how chronic environmental stress drives immune dysfunction in cold tumors

Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.

SourcePusan National University·JournalSignal Transduction and Targeted Therapy·TypeExperimental study·DateAug 18, 2026

Preoperative chemo-immunotherapy more effective than immunotherapy alone in patients with head and neck cancer

A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJAMA Otolaryngology–Head & Neck Surgery·DateAug 13, 2026